[go: up one dir, main page]

WO2008058167A2 - Méthodes de traitement de troubles associés à l'activation du complément - Google Patents

Méthodes de traitement de troubles associés à l'activation du complément Download PDF

Info

Publication number
WO2008058167A2
WO2008058167A2 PCT/US2007/083860 US2007083860W WO2008058167A2 WO 2008058167 A2 WO2008058167 A2 WO 2008058167A2 US 2007083860 W US2007083860 W US 2007083860W WO 2008058167 A2 WO2008058167 A2 WO 2008058167A2
Authority
WO
WIPO (PCT)
Prior art keywords
disease
pharmaceutical composition
carbon atoms
straight
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/083860
Other languages
English (en)
Other versions
WO2008058167A3 (fr
Inventor
M. Edward Medof
Feng Lin
Qing Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Priority to US12/514,024 priority Critical patent/US20100063146A1/en
Publication of WO2008058167A2 publication Critical patent/WO2008058167A2/fr
Publication of WO2008058167A3 publication Critical patent/WO2008058167A3/fr
Anticipated expiration legal-status Critical
Priority to US15/339,367 priority patent/US20170189366A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates generally to a method for treating or preventing a complement mediated disorders, and more particularly to a method for treating or preventing T cell autoreactivity in autoimmune disease associated with complement activation and/or complement activation mediated disorders.
  • T-cell mediated diseases represent a large number of immune system disorders.
  • T-cells are thought to be the cells that start and perpetuate autoimmune diseases.
  • Autoimmune diseases are a group of eighty serious, chronic illnesses that afflict millions of people in the United States alone.
  • Autoimmune diseases are characterized by reactivity of the immune system to endogenous (self) antigens. These immune responses to self antigens -?-
  • Ophthalmic diseases may lead to vision loss and can include front-of-eye diseases such as corneal edema, anterior uveitis, pterygium, corneal diseases or opacifications with an exudative or inflammatory component, and conjunctivitis, as well as back-of-eye diseases such as exudative macular degeneration, macular edema arising from laser treatment of the retina, diabetic retinopathy, and age-related macular degeneration (AMD).
  • Front-of-eye diseases such as corneal edema, anterior uveitis, pterygium, corneal diseases or opacifications with an exudative or inflammatory component, and conjunctivitis
  • back-of-eye diseases such as exudative macular degeneration, macular edema arising from laser treatment of the retina, diabetic retinopathy, and age-related macular degeneration (AMD).
  • Back-of-eye diseases comprise the largest number of causes for vision loss in the developed
  • the present invention relates to a method for treating disorders associated with intraoccular complement activation or T cell autoreactivity in a subject.
  • the method includes administering a therapeutically effective amount of a pharmaceutical composition to the subject.
  • the pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt thereof having anti-complement activity.
  • the amidine compound can have the following general formula (I):
  • Ri and R 2 each represent a hydrogen atom, or a straight or branched chain alkyl group of 1 to 6 carbons; wherein R 3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R 4 — B — (CH 2 ) n — where n is 1 to 2,
  • B is — O — or — NH —
  • R 4 is a hydrogen atom, R 5 — CO — or
  • R 5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms; and wherein R] and R 3 taken together via 2 to 4 carbon atoms optionally form a ring containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
  • the amidine compound can have the formula (II):
  • Another aspect of the present invention relates to a method of treating T cell mediated autoimmune disorders in a subject.
  • the method includes administering a therapeutically effective amount of a pharmaceutical composition to the subject.
  • the pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt thereof having anti-complement activity.
  • the amidine compound can have the following general formula (I):
  • Ri and R 2 each represent a hydrogen atom, or a straight or branched chain alkyl group of 1 to 6 carbons; wherein R 3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R 4 — B — (CH 2 ) n — where n is 1 to 2,
  • B is — O— or -NH-
  • R 4 is a hydrogen atom, R 5 — CO — or
  • R 5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms; and wherein R] and R 3 taken together via 2 to 4 carbon atoms optionally form a ring containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
  • the amidine compound can have the formula (II):
  • a further aspect of the present invention relates to a method of treating retinal or choroidal degenerative disease in a subject.
  • the method includes administering a therapeutically effective amount of a pharmaceutical composition to the subject.
  • the pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt thereof having anti-complement activity.
  • the amidine compound can have the following general formula (I):
  • Ri and R 2 each represent a hydrogen atom, or a straight or branched chain alkyl group of 1 to 6 carbons; wherein R 3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R 4 — B — (CH 2 ) n — where n is 1 to 2,
  • B is — O — or — NH —
  • R 4 is a hydrogen atom, R 5 — CO — or
  • R 5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms; and wherein R] and R 3 taken together via 2 to 4 carbon atoms optionally form a ring containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
  • the amidine compound can have the formula (II):
  • Figs. IA-C are a series of graphs showing the ability of an amidine compound according to the present invention to inhibit alternative pathway-dependent amplification of C3 cleavage.
  • factor B, factor D, and C3 were mixed in the absence or presence of increasing concentrations of the amidine compound and generation of C3a was quantified by ELISA.
  • Fig. IA factor B, factor D, and C3 were mixed in the absence or presence of increasing concentrations of the amidine compound and generation of C3a was quantified by ELISA.
  • IB, factor B, factor D, C3, and a limiting amount of factor H were mixed in the absence or presence of two doses of the amidine compound following initial deposition of C3b on Bruch's membrane via anti-CEP initiated classical pathway activation.
  • factor B, factor D, C3, and a limiting amount of factor H were mixed in the absence or presence of two doses of the amidine compound following initial deposition of C3b on the RPE-43 cell line by anti-class I monomorphic antibody;
  • Figs. 2A-B are a series of flat mounts showing the effects on lesion size of the amidine compound in a laser-induced CNV mouse model.
  • Fig. 2A shows representative flat mounts of the RPE-Bruch' s membrane-choroid complex in control-treated mice.
  • Fig. 2B shows representative flat mounts of the RPE-Bruch' s membrane-choroid complex of mice treated with the amidine compound.
  • Fig. 3 is a graph illustrating in vivo inhibitory effect of FUT-175 in an EAE mouse model.
  • One aspect of the present invention relates to a method of treating T-cell mediated diseases and/or T-cell autoreactivity in autoimmune diseases.
  • Treatment is used herein to mean to reduce (wholly or partially) the symptoms, duration or severity of a disease, including curing the disease, or to prevent the disease.
  • T-cell mediated diseases can include graft rejection, graft versus host disease, unwanted delayed-type hypersensitivity reactions (such as delayed-type allergic reactions), T-cell mediated pulmonary diseases, and autoimmune diseases.
  • T-cell mediated pulmonary diseases include sarcoidosis, hypersensitivity pneumonitis, acute interstitial pneumonitis, alveolitis, pulmonary fibrosis, idiopathic pulmonary fibrosis and other diseases characterized by inflammatory lung damage.
  • Autoimmune diseases include multiple sclerosis, neuritis, polymyositis, psoriasis, vitiligo, Sjogren's syndrome, rheumatoid arthritis, Type 1 diabetes, inflammatory bowel diseases (e.g., Crohn's disease and ulcerative colitis), celiac disease, glomerulonephritis, scleroderma, sarcoidosis, autoimmune thyroid diseases (e.g., Hashimoto's thyroiditis and Graves disease), myasthenia gravis, Addison's disease, autoimmune uveoretinitis, pemphigus vulgaris, primary biliary cirrhosis, pernicious anemia, and systemic lupus erythematosis.
  • inflammatory bowel diseases e.g., Crohn's disease and ulcerative colitis
  • celiac disease e.g., Crohn's disease and ulcerative colitis
  • celiac disease glomerul
  • T-cell mediated diseases can contribute to the pathology of T-cell mediated diseases and that amidine compounds, which exhibit anti-complement activity can be systemically administered to animals with a T-cell mediated disease, such as multiple sclerosis, to inhibit, reduce, ameliorate T-cell autoreativity and activation and treat the T-cell mediated disease or autoimmune disease.
  • a T-cell mediated disease such as multiple sclerosis
  • the T-cell mediated disease or autoimmune diseases can therefore be treated by administering to an animal or subject in need thereof an effective amount of an amidine compound or pharmaceutically acceptable salt thereof that exhibits anti-complement activity.
  • Amidine compounds that exhibit anti-complement activity and that can be used in the therapeutic method of the present invention include, for example, amidine compounds disclosed and claimed in U.S. Pat. Nos. 4,514,416; 4,454,338; 4,570,006; 4,777,182; 5,514,713; and 5,932,603, all of which are hereby incorporated by reference in their entireties.
  • the at least one amidine compound can have the following general formula (I):
  • R] and R 2 each represent a hydrogen atom, or a straight or branched chain alkyl group of 1 to 6 carbons; wherein R 3 represents a hydrogen, a straight or branched chain alkyl group of 1 to 6 carbon atoms or a group of the formula R 4 — B — (CH 2 ) n — where n is 1 to 2,
  • B is — O — or — NH —
  • R 4 is a hydrogen atom, R 5 — CO — or
  • R 5 is a straight or branched chain alkyl group of 1 to 15 carbon atoms; And Rl and R3 taken together via 2 to 4 carbon atoms may form a ring optionally containing double bonds and straight or branched alkyl groups of 1 to 4 carbon atoms as substituents or a pharmaceutically acceptable salt thereof.
  • the at least one amidine compound can be 6- amidino-2-naphthyl-4-guanidinobenzoate, which has the following formula (II):
  • a pharmaceutically acceptable salt thereof e.g., -amidino-2-naphthyl-4- guanidinobenzoate dimethanesulfonate
  • Amidine compounds of the present invention can be provided in the form of pharmaceutical compositions.
  • Pharmaceutical compositions can be administered to any mammal that can experience the beneficial effects of the amidine compounds of the present invention. Foremost among such mammals are humans, although the present invention is not intended to be so limited.
  • compositions of the present invention can be administered by any means that achieve their intended purpose.
  • administration can be by parenteral, subcutaneous, intravenous, intraarticular, intrathecal, intramuscular, intraperitoneal, or intradermal injections, or by transdermal, buccal, oromucosal, ocular routes or via inhalation.
  • parenteral administration is particularly preferred.
  • the dosage administered will be dependent upon the age, health, and weight of the subject, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • amidine compound When referring to an amidine compound of the present invention, applicants intend the phrase "amidine compound” to encompass not only the specified molecular entity, but also its pharmaceutically acceptable, pharmacologically active analogs, including, but not limited to, salts, esters, amides, prodrugs, conjugates, active metabolites, and other such derivatives, analogs, and related compounds.
  • treatment of a subject by administration of an amidine compound of the present invention encompasses prevention in a subject susceptible to developing a retinal or choroidal degenerative disease (e.g., at a higher risk, as a result of genetic predisposition, environmental factors, or the like) and/or in treatment of a subject having a retinal or choroidal degenerative disease.
  • Effective amounts in terms the foregoing method, are amounts of the at least one amidine compound of formulas (I- III) effective to treat or prevent a retinal or choroidal degenerative disease in a subject.
  • phrases "pharmaceutically acceptable” should be understood to mean a material which is not biologically or otherwise undesirable, i.e., the material may be incorporated into a pharmaceutical composition administered to a subject without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained.
  • pharmaceutically acceptable refers to a pharmaceutical carrier or excipient, it is implied that the carrier or excipient has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.
  • “Pharmacologically active” refers to a derivative or analog having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
  • Some of the amidine compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms.
  • the present invention is also meant to encompass racemic mixtures, resolved forms and mixtures thereof, as well as the individual enantiomers that may be separated according to methods that are well know to those of ordinary skill in the art.
  • the amidine compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both E and Z geometric isomers.
  • stereoisomers is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
  • asymmetric center or “chiral center” refers to a carbon atom to which four different groups are attached.
  • enantiomer or “enantiomeric” refers to a molecule that is nonsuperimposeable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image rotates the plane of polarized light in the opposite direction.
  • racemic refers to a mixture of equal parts of enantiomers and which is optically inactive.
  • resolution refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.
  • enantiomeric excess refers to a mixture wherein one enantiomer is present is a greater concentration than its mirror image molecule.
  • the pharmaceutical compositions of the present invention can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the amidine compounds into preparations that can be used pharmaceutically.
  • the pharmaceutical compositions of the present invention may be manufactured in a manner that is, itself, known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes.
  • pharmaceutical compositions for oral use for example, can be obtained by combining amidine compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as saccharides, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders, such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
  • fillers such as saccharides, for example, lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example, tricalcium phosphate or calcium hydrogen phosphate, as well as binders, such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth,
  • disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
  • Auxiliaries can include flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • Dragee cores may be provided with suitable coatings, that if desired, are resistant to gastric juices.
  • concentrated saccharide solutions can be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol, and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate, may be used.
  • Slow-release and prolonged-release formulations may be used with particular excipients such as methacrylic acid-ethylacrylate copolymers, methacrylic acid-ethyl acrylate copolymers, methacrylic acid-methyl methacrylate copolymers and methacrylic acid-methyl methylacrylate copolymers.
  • Dye stuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft-sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain the active compounds in the form of granules that may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids such as fatty oils or liquid paraffin.
  • stabilizers may be added.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. Especially preferred salts can include maleate, fumarate, succinate, S, S tartrate, or R,R tartrate.
  • suspensions of the amidine compounds as appropriate oily injection suspensions can be administered.
  • Suitable lipophilic solvents or vehicles can include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400).
  • Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • a subject with a T-cell mediated autoimmune disease such as multiple sclerosis, may be treated by administering a therapeutically effective amount of a pharmaceutical composition containing an amidine compound, such as an amidine compound having the formula (II).
  • the pharmaceutical composition may be administered to the subject, for example, parenterally.
  • complement activation of the T-cells may be reduced or inhibited.
  • Fig. 3 which illustrate the in vivo inhibitory effect of FUT- 175 in an EAE mouse, the clinical score of the EAE mice treated with FUT- 175 was substantially improved with respect to the control EAE mice where no FUT- 175 was administered.
  • Another aspect of the present invention relates generally to a method for treating or preventing a retinal or choroidal degenerative disease that is associated with intraoccular complement activation that is derived from systemic (e.g., serum or blood) and/or local (T-cell or antigen presenting cell) complement activation.
  • the retinal or choroidal degenerative disease can include, for example, age-related macular degeneration (AMD). It was found that an amidine compound, such as 6-amidino-2-n «/??/z_y/-4-guanidinobenzoate dimethanesulfonate or FUT- 175, suppresses alternative pathway-dependent amplification of complement activation in vitro, and significantly reduces choroidal neovascularization in vivo.
  • AMD age-related macular degeneration
  • the present invention provides a method for treating or preventing a retinal or choroidal degenerative disease in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising at least one amidine compound with anti-complement activity, such as described above.
  • the amidine compound can be selected from formulas (I- II) below.
  • the at least one amidine compound may be combined or mixed with one or more other agents, such as non-toxic pharmaceutically acceptable carriers, diluents, adjuvants and/or other ingredients, if desired.
  • a retinal or choroidal degenerative disease may be treated or prevented by administering a therapeutically effective amount of a pharmaceutical composition comprising at least one amidine compound selected from formulas (I-II).
  • a retinal or choroidal degenerative disease may generally include diseases or conditions of the eye associated with neovascularization, including, for example, retinal and/or choroidal neovascularization.
  • a retinal or choroidal degenerative disease can include, without limitation, wet macular degeneration, dry macular degeneration, early-onset macular degeneration, atrophic macular degeneration, neovascular macular degeneration, AMD, choroidal neovascularization, retinal pigment epithelium detachment, atrophy of retinal pigment epithelium, Best's disease, vitelliform, Stargardt's disease, juvenile macular dystrophy, fundus flavimaculatus, Behr's disease, Sorsby's disease, Doyne's disease, honeycomb dystrophy, North Carolina macular dystrophy, pattern dystrophy, dominant drusen, malattia leventinese, chorioretinal degenerations, retinal degenerations, photoreceptor degenerations, RPE degenerations, mucopolysaccharidoses, and rod-cone dystrophies.
  • a subject having a retinal or choroidal degenerative disease may be treated by administering a therapeutically effective amount of a pharmaceutical composition containing an amidine compound, such as having formula (II).
  • the pharmaceutical composition may be administered to the subject parenterally, for example.
  • alternative pathway-dependent amplification of complement activation may be reduced or inhibited.
  • administration of the pharmaceutical composition may reduce or inhibit C3b activation and, in turn, reduce or inhibit choroidal neovascularization.
  • Treatment with the pharmaceutical composition of the present invention may reduce or prevent AMD and thus reduce or prevent progressive vision loss in the subject.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement ou de prévention d'un trouble induit par des lymphocytes T activés par le complément, chez un sujet, cette méthode consistant à administrer au sujet une quantité thérapeutiquement efficace d'une composition pharmaceutique. La composition pharmaceutique comprend au moins un composé amidine ou un sel pharmaceutiquement acceptable.
PCT/US2007/083860 2006-11-07 2007-11-07 Méthodes de traitement de troubles associés à l'activation du complément Ceased WO2008058167A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/514,024 US20100063146A1 (en) 2006-11-07 2007-11-07 Method for treating disorders related to complement activation
US15/339,367 US20170189366A1 (en) 2006-11-07 2016-10-31 Method for treating disorders related to complement activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85725906P 2006-11-07 2006-11-07
US60/857,259 2006-11-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/514,024 A-371-Of-International US20100063146A1 (en) 2006-11-07 2007-11-07 Method for treating disorders related to complement activation
US15/339,367 Continuation US20170189366A1 (en) 2006-11-07 2016-10-31 Method for treating disorders related to complement activation

Publications (2)

Publication Number Publication Date
WO2008058167A2 true WO2008058167A2 (fr) 2008-05-15
WO2008058167A3 WO2008058167A3 (fr) 2008-12-24

Family

ID=39365333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083860 Ceased WO2008058167A2 (fr) 2006-11-07 2007-11-07 Méthodes de traitement de troubles associés à l'activation du complément

Country Status (2)

Country Link
US (2) US20100063146A1 (fr)
WO (1) WO2008058167A2 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6133173A (ja) * 1984-07-25 1986-02-17 Torii Yakuhin Kk アミジン化合物
US5238964A (en) * 1990-04-05 1993-08-24 Torii & Co., Ltd. Agent for treatment of cerebrovascular contraction
US5364884A (en) * 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
DE69409471T2 (de) * 1993-12-03 1998-08-27 Ono Pharmaceutical Co Amidinophenolderivate mit Phospholipase A2 inhibitorischer Wirkung
DK0891426T3 (da) * 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
FR2801053B1 (fr) * 1999-11-16 2004-06-25 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation et leur application a titre de medicaments
US20030049260A1 (en) * 2001-07-26 2003-03-13 Leonard Bell Method of improving cognitive function
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2006123675A1 (fr) * 2005-05-17 2006-11-23 Santen Pharmaceutical Co., Ltd. Agent protecteur de neurocyte comprenant un derive amidino en tant que substance active

Also Published As

Publication number Publication date
WO2008058167A3 (fr) 2008-12-24
US20170189366A1 (en) 2017-07-06
US20100063146A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
US8822492B2 (en) Use of huperzine for disorders
US9155719B2 (en) N-acetyl-DL-leucine, neuroprotective and retinoprotective medicament
WO2013070879A1 (fr) Méthodes de traitement de lésion de la moelle épinière par des antagonistes du récepteur du lpa
EP2588099A2 (fr) Procédés de traitement du syndrome des jambes sans repos
EP2590645A2 (fr) Procédés de traitement du trouble bipolaire
JP2021503449A (ja) 眼障害の処置のための組成物及び方法
RU2316341C2 (ru) Применение атазанавира в терапии вич-инфекции
US20170189366A1 (en) Method for treating disorders related to complement activation
HUT71497A (en) New pharmaceutical use of 1,2,3,4,4a,5,10,10a-octahydro-benzo(g) quinoline derivatives
Chen A COMPARATIVE STUDY OF EPHEDRINE, PSEUDO-EPHEDRINE AND ß-PHENYL-ETHYLAMINE: WITH REFERENCE TO THEIR EFFECTS ON THE PUPIL AND ON THE BLOOD PRESSURE
US20240261248A1 (en) Methods for treating autism spectrum disorders (asd)
EP3558378A1 (fr) Combinaisons de médicaments à faibles doses destinées à être utilisées dans la prévention et le traitement d'une lésion neuronale
WO2014111525A2 (fr) Nouvelles polythérapies pour le traitement de maladies du système nerveux
CA1209047A (fr) Compose therapeutique contenant un analogue du piracetam
WO2018220457A1 (fr) Vitamine b1 à doses élevées destinée à être utilisée dans le traitement médical des symptômes moteurs de certaines maladies neurodégénératives sporadiques et d'origine génétique, et de l'algie vasculaire de la face et de la céphalée migraineuse
US20240423965A1 (en) Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
US20250115596A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
US20240207262A1 (en) Prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis
WO2004105756A2 (fr) Combinaison contenant un agent neuroprotecteur et un agent se fixant a la gadph, et utilisation pharmaceutique associee
WO1998017214A1 (fr) Procede de traitement d'une demence provoquee par le syndrome d'immunodeficit acquis
US20220362202A1 (en) Drug For Treating And Preventing Dementia
WO2017106288A1 (fr) Nouveaux composés et procédés pour le traitement de la maladie d'alzheimer et/ou de l'angiopathie amyloïde cérébrale
JPH06211693A (ja) 心筋虚血の治療剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871384

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12514024

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07871384

Country of ref document: EP

Kind code of ref document: A2